Subscribe
shutterstock_1123492958_willy_barton
Willy Barton / Shutterstock.com
14 June 2019Americas

GSK unites with CRISPR pioneer Doudna

British-based pharmaceutical company GSK has entered into a five-year collaboration with the U niversity of California to explore how gene mutations cause disease and accelerate drug discovery.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
GSK unites with 23andMe amid R&D revamp
27 July 2018   GSK revealed its new approach to research and development earlier this week, including a partnership with DNA testing company 23andMe.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Americas
GSK unites with 23andMe amid R&D revamp
27 July 2018   GSK revealed its new approach to research and development earlier this week, including a partnership with DNA testing company 23andMe.

More on this story

Americas
GSK unites with 23andMe amid R&D revamp
27 July 2018   GSK revealed its new approach to research and development earlier this week, including a partnership with DNA testing company 23andMe.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims